<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2016//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_160101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">27525588</PMID>
        <DateCreated>
            <Year>2016</Year>
            <Month>8</Month>
            <Day>15</Day>
        </DateCreated>
        <DateRevised>
            <Year>2016</Year>
            <Month>8</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-0142</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer</Title>
                <ISOAbbreviation>Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/cncr.30256</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor receptor, in combination with chemotherapy, in the first-line treatment of patients with recurrent/metastatic squamous cell cancer of the head and neck.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">On day 1, duligotuzumab at a dose of 1650?mg intravenously was combined with cisplatin at a dose of 100?mg/m(2) and 5-fluorouracil at a dose of 1000?mg/m(2) /day on days 1 to 4 in treatment arm A, or carboplatin (area under the curve, 6?mg/mL/min) and paclitaxel (at a dose of 200?mg/m(2) ) in treatment arm B. Up to 6 cycles (21 days/cycle) were followed by duligotuzumab maintenance until disease progression or intolerable toxicity occurred.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine patients in arm A and 15 patients in arm B received a median of 6 cycles of chemotherapy, and a median of 11 cycles (arm A) and 9 cycles (arm B) of duligotuzumab. Dose-limiting toxicities occurred in 3 patients in arm A and 1 patient in arm B. Grade???3 treatment-related adverse events (graded according to graded according to National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]) in???3 patients were neutropenia (5 patients), hypokalemia (4 patients), dehydration (3 patients), anemia (3 patients), and diarrhea (3 patients) in arm A, and neutropenia (8 patients), anemia (5 patients), febrile neutropenia (4 patients), leukopenia (3 patients), thrombocytopenia (3 patients), and hypomagnesemia (3 patients) in arm B. The chemotherapy dose was reduced in 19 of 24 patients. Sixteen patients (67%) demonstrated objective responses regardless of human papillomavirus status or neuregulin 1 (NRG1) mRNA expression (arm A: 2 confirmed complete responses and 4 confirmed partial responses; arm B: 2 confirmed complete responses and 8 confirmed partial responses).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Duligotuzumab in combination with cisplatin/5-fluorouracil or carboplatin/paclitaxel demonstrated encouraging activity in patients with recurrent/metastatic squamous cell cancer of the head and neck; an association with increased frequency and severity of select adverse events relative to historical data was suggestive of the potentiation of chemotherapy-related adverse events. Cancer 2016. ? 2016 American Cancer Society.</AbstractText>
                <CopyrightInformation>? 2016 American Cancer Society.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jimeno</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Machiels</LastName>
                    <ForeName>Jean-Pascal</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>King Albert II Institute, Medical Oncology Service, Saint-Luc University Clinic and Clinical and Experimental Research Institute (Pole MIRO), Catholic University of Louvain, Brussels, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Wirth</LastName>
                    <ForeName>Lori</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Specenier</LastName>
                    <ForeName>Pol</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Seiwert</LastName>
                    <ForeName>Tanguy Y</ForeName>
                    <Initials>TY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Mardjuadi</LastName>
                    <ForeName>Feby</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>King Albert II Institute, Medical Oncology Service, Saint-Luc University Clinic and Clinical and Experimental Research Institute (Pole MIRO), Catholic University of Louvain, Brussels, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Xiaodong</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Kapp</LastName>
                    <ForeName>Amy V</ForeName>
                    <Initials>AV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Royer-Joo</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Penuel</LastName>
                    <ForeName>Elicia</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>McCall</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Pirzkall</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Clement</LastName>
                    <ForeName>Paul M</ForeName>
                    <Initials>PM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType UI="">JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cancer</MedlineTA>
            <NlmUniqueID>0374236</NlmUniqueID>
            <ISSNLinking>0008-543X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antibody</Keyword>
            <Keyword MajorTopicYN="N">clinical trial</Keyword>
            <Keyword MajorTopicYN="N">duligotuzumab</Keyword>
            <Keyword MajorTopicYN="N">epidermal growth factor receptor (EGFR)</Keyword>
            <Keyword MajorTopicYN="N">human epidermal growth factor receptor 3 (HER3)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.30256</ArticleId>
            <ArticleId IdType="pubmed">27525588</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
